Supplementary Figure S2 from Early Clearance of Plasma Epidermal Growth Factor Receptor Mutations as a Predictor of Outcome on Osimertinib in Advanced Non-Small Cell Lung Cancer; Exploratory Analysis from AURA3 and FLAURA

Jhanelle E. Gray; Myung‐Ju Ahn; Geoffrey R. Oxnard; Frances A. Shepherd; Fumio Imamura; Ying Cheng; Isamu Okamoto; Byoung Chul Cho; Meng‐Chih Lin; Yi−Long Wu; Margarita Majem; Oliver Gautschi; Michael Boyer; Krishna C. Bulusu; Aleksandra Markovets; J. Carl Barrett; Rachel Hodge; Astrid McKeown; Ryan J. Hartmaier; Juliann Chmielecki; Vassiliki A. Papadimitrakopoulou; Suresh S. Ramalingam

doi:10.1158/1078-0432.27032563.v1

Abstract

Correlation between EGFRm allelic fraction at baseline by ddPCR (Biodesix) and NGS (Guardant Health) analyses in A, patients from the AURA3 trial (n = 202) and B, patients from the FLAURA trial (n = 347). Abbreviations: ddPCR, droplet digital PCR; EGFRm, epidermal growth factor receptor mutation (ex19del or L858R); NGS, next-generation sequencing.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Gray et al. (2024) studied this question.

synapsesocial.com/papers/68e586b5b6db643587522d5b https://doi.org/10.1158/1078-0432.27032563.v1

View Full Paper

Ask AI

Bookmark

Share

Supplementary Figure S2 from Early Clearance of Plasma Epidermal Growth Factor Receptor Mutations as a Predictor of Outcome on Osimertinib in Advanced Non-Small Cell Lung Cancer; Exploratory Analysis from AURA3 and FLAURA

Abstract

Discussion

Cite This Study

Supplementary Figure S2 from Early Clearance of Plasma Epidermal Growth Factor Receptor Mutations as a Predictor of Outcome on Osimertinib in Advanced Non-Small Cell Lung Cancer; Exploratory Analysis from AURA3 and FLAURA

Abstract

Discussion

Cite This Study

Keep reading

Keep reading